Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $16.32, but opened at $15.65. GH Research shares last traded at $15.06, with a volume of 844,915 shares.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of GH Research in a report on Monday, January 27th. Canaccord Genuity Group cut their price objective on shares of GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, November 18th.
View Our Latest Analysis on GH Research
GH Research Stock Up 2.7 %
The stock's fifty day moving average is $9.03 and its 200-day moving average is $9.03.
Institutional Trading of GH Research
A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. boosted its stake in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,686,689 shares of the company's stock after purchasing an additional 85,000 shares during the quarter. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 at the end of the most recent quarter. Institutional investors own 56.90% of the company's stock.
GH Research Company Profile
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Recommended Stories
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
